Celldex Therapeutics Stock Forecast
NASDAQ: CLDXHealth CareBiotechnology: In Vitro & In Vivo Diagnostic SubstancesUSD
Market open · Delayed 15 min · as of Oct 8, 12:19 PM ET
CLDX analyst consensus
Consensus (15 analysts)
strong_buy
Avg. price target
$63.07+118.84%
- Strong buy 2
- Buy 12
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 15 Wall Street analysts covering Celldex Therapeutics (2026-10-07), 14 rate the stock a buy or strong buy, 1 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "strong_buy". The average 12-month price target is $63.07, with a high estimate of $100.00 and a low estimate of $28.00. The average target implies upside of 118.8% from the current price of $28.82.
The spread between the highest and lowest targets is 257.1%, a wide range that reflects significant disagreement among analysts. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for CLDX.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 2 | 13% |
| Buy | 12 | 80% |
| Hold | 1 | 7% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-07.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $28.00 | -2.85% |
| Average target | $63.07 | +118.84% |
| High target | $100.00 | +246.98% |